December 5, 2010

ASH 2010: MMRF Trip Report for Friday December 3 and Saturday December 4 Louise Perkins, PhD


The first several days at ASH have been invigorating as the progress towards the next new treatments for multiple myeloma and other blood cancers is shared at this annual international meeting of the American Society of Hematology. ASH is one of the most important scientific gatherings for researchers and doctors studying MM and related cancers.

The annual MMRF symposium on Friday night helped to kick off the meeting. This year's session truly excelled in its scientific content for doctors on the continuing evolution of myeloma patient care. Hats off to MMRF's Anne Quinn Young and Dr. Paul Richardson for that work.

On Saturday, the MMRF met with more than 10 pharmaceutical companies to identify new collaborations accelerating the next treatments. From these meetings will come not only new validation projects to prioritize the next generation of drugs but also new clinical trials for the MMRC. In addition, we learned that there are numerous MM Phase III studies being planned for 2011, some of which are of drugs already showing promise and which also includes drugs that have been evaluated in MMRC clinical trials.

While amazing progress has been made in the last decade, there is still a great deal to be done. The MMRF is here at ASH on behalf of our patients not just to monitor the scientific state-of-the-field, but to actively ensure that there is a continuum of progress. How do we do that? We work with companies and academic researchers and foster projects that build on recent successes and takes advantage of the power of collaboration among companies, academic researchers and patients.